PMC8861469_01
D-dimer levels of the patient over three weeks.. Note: bold numbers including those in boxes indicate batches of therapy regimens.
f1000research-10-77714-g0000.jpg
PMC8861469_01_f1000research-10-77714-g0000.jpg
f1
On the third day, anticoagulant heparin (9000 IU) was given since there was a sudden spike of D-dimer from 160 to 1015 ng/mL in a day that was beyond the normal value (<500 ng/mL) ( Figure 1).
Partial Thromboplastin Time (aPTT), Prothrombin Time (PT), Fibrinogen, and Thrombocyte levels of the patient.
f1000research-10-77714-g0001.jpg
PMC8861469_01_f1000research-10-77714-g0001.jpg
f2
Time (PT), fibrinogen, and platelets were performed from the first day of treatment for COVID-19. These markers showed unremarkable changes. The patient showed normal or slightly elevated levels of aPTT and PT in the range of 23.1-34.8 s and 10.1-15.4 s, respectively (normal value: 23.0-30.2 s for APTT and 10.1-11.9 s for PT) ( Figure 2). The PT level increase was still less than 3 seconds, so the elevation had not fulfilled the criteria as in guidelines of The International Society for Thrombosis and Haemostasis (ISTH).    
Erythrocyte sedimentation rate (ESR), C-reactive protein (CRP), Ferritin, and Neutrophil-Lymphocyte Ratio (NLR) of the patients.
f1000research-10-77714-g0002.jpg
PMC8861469_01_f1000research-10-77714-g0002.jpg
f3
When D-dimer increased for the second time, there was a surge of hs-CRP and ESR ( Figure 3) of 0.56 mg/dL and 15-25 mm/hour, respectively, which were above the normal range of <0.5 mg/dL and < 10 mm/hour, respectively.
CT-scan chest/lung with 128 slices of the patient on the 12th day of treatment.. Circles indicate ground-glass appearance on the right lobe lung.
f1000research-10-77714-g0003.jpg
PMC8861469_01_f1000research-10-77714-g0003.jpg
f4
On the 12th day, when D-dimer increased for the second time, accompanied by an increase in other inflammatory markers, the patient underwent a chest CT scan, which showed a minimal ground glass appearance in the right lobe of the lung ( Figure 4).
HbA1C, fasting plasma glucose, and random plasma glucose of the patient.
f1000research-10-77714-g0004.jpg
PMC8861469_01_f1000research-10-77714-g0004.jpg
f5
The data of random plasma glucose increased inconsistently despite insulin administration ( Figure 5).